Embark is a canine genomics and biotechnology company that offers dog DNA testing services to consumers, breeders, and veterinarians. Their goal is to help pet owners better understand their dog's health and risk for heritable diseases, and to advance canine DNA research.

Embark

Embark offers the most comprehensive, most accurate dog DNA test on the market. An Embark dog DNA test gives pet owners information about their dog’s breed, ancestry, health, and more — all with just a simple cheek swab. The company uses twice as much genetic information as any other test available and features the world’s only canine DNA relative finder. Pet owners can use Embark to test for over 210 genetic health conditions, so they can make the best choices for their dog. Launched by two brothers, Embark is an official research partner with Cornell University College of Veterinary Medicine and has a mission to end preventable disease in dogs.

Third Kind Venture Capital

Section 32 F-Prime Capital

FJ Labs

Slow Ventures

Freestyle Capital

Anne Wojcicki

SoftBank Vision Fund

Embark Veterinary

Embark Veterinary is heading to Orlando for VMX 2024! Come on over and meet the team at booth #1978 and be sure to check out our CE session: Let's Get Clinical: Real world management of common testable canine genetic conditions on Monday, January 15th at 5:45 PM.

🐶 🧬 We're excited to share that Embark Veterinary dog DNA tests, including the Embark for Veterinarians 10-pack, the Breed ID, and the Breed + Health tests, are now available on Vetcove.com. 
✨ Buying dog DNA tests has never been easier! ✨ 
✅ Check it out: https://lnkd.in/eZx97t4S 

We’re excited to announce that Amish Desai, who joined Embark in 2022 as chief financial officer, is stepping into a new role as Embark’s CEO! 🌟 With a focus on our core DNA offerings as well as strategic expansions into new channels and products, Amish is dedicated to helping dog owners form stronger bonds with their best friends.

Learn more here:
https://lnkd.in/eWwUqVt6

Metric
Company Name	Embark
Symbol
MSH ID	COM:EMBARKVET
Market	PRIVATE
Sector	Biotechnology
Industry	Genetic Genealogy
Country	US
Stage
Employee Count	120
Website	embarkvet.com
LinkedIn	embark-vet
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	56.16
28-Day Growth Score	52.66
90-Day Growth Score	59.72
365-Day Growth Score	75.24

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:EMBARKVET

Embark

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue